DeepMed Research

JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Neoplasm Metastases

Interventions: Drug: Trabectedin
Drug: Ketoconazole
Drug: Dexamethasone or equivalent steroid

First Posted Date: 2010-12-24

Last Posted Date: 2015-10-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT01267084

Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: CA-18C3

First Posted Date: 2010-12-15

Last Posted Date: 2021-02-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT01260545

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Phase 3

Terminated

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Placebo
Drug: CNTO 148 (Golimumab)
Drug: Methotrexate

First Posted Date: 2010-10-29

Last Posted Date: 2016-04-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 173

Registration Number: NCT01230827

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Phase 1

Completed

Conditions: Age-related Macular Degeneration

Interventions: Biological: CNTO 2476
Procedure: iTrack Model 275 micro catheter

First Posted Date: 2010-10-22

Last Posted Date: 2017-08-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 39

Registration Number: NCT01226628

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Phase 1

Completed

Conditions: Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Plasma Cell Neoplasm

Interventions: Biological: Siltuximab

First Posted Date: 2010-10-13

Last Posted Date: 2015-01-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 30

Registration Number: NCT01219010

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Phase 2

Completed

Conditions: Inflammation
Crohn's Disease

Interventions: Drug: NNC 0142-0000-0002
Drug: Placebo

First Posted Date: 2010-09-16

Last Posted Date: 2016-08-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 78

Registration Number: NCT01203631

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Milwaukee, Wisconsin, United States

Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)

Phase 2

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: NNC0142-0002
Drug: placebo

First Posted Date: 2010-08-13

Last Posted Date: 2016-10-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 63

Registration Number: NCT01181050

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Phase 3

Completed

Conditions: Pain

Interventions: Drug: R331333 (referred to as JNS024 ER or CG5503)
Drug: Oxycodone CR

First Posted Date: 2010-07-19

Last Posted Date: 2017-07-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 343

Registration Number: NCT01165281

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Canagliflozin 300 mg
Drug: Sitagliptin 100 mg
Drug: Metformin
Drug: Sulphonylurea

First Posted Date: 2010-06-04

Last Posted Date: 2015-01-15

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 756

Registration Number: NCT01137812

Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents

Phase 2

Completed

Conditions: Postoperative Pain
Pain, Postoperative

Interventions: Drug: Tapentadol (OS) Oral Solution

First Posted Date: 2010-06-02

Last Posted Date: 2014-07-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 45

Registration Number: NCT01134536

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy